• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

June 23, 2025 By Sean Whooley

Biolinq intradermal glucose sensor

A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, biolinq

A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology

June 22, 2025 By Sean Whooley

GlucoTrack implantable continuous blood glucose monitor CBGM

Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, Glucotrack

Glucotrack to effect a reverse stock split

June 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]

Filed Under: Business/Financial News, Diabetes, Featured, Implants, Patient Monitoring, Technology, Wall Street Beat Tagged With: Glucotrack

SpyGlass Pharma raises $75M for drug delivery platform

June 2, 2025 By Sean Whooley

SpyGlass Pharma Intraocular Lens IOL drug delivery platform

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Optical/Ophthalmic Tagged With: SpyGlass Pharma

Vivani files with SEC to spin off neurostim business, focus on drug delivery implants

May 29, 2025 By Sean Whooley

Vivani Medical Cortigent

Vivani Medical (Nasdaq:VANI) announced today that it filed a Form 10 registration statement with the SEC to spin off its neurostimulation unit. The company said earlier this year that it plans to spin off Cortigent, a division that develops brain implants. The company wants to create two focused companies dedicated to driving current and future […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Implants, Neurological Tagged With: Cortigent, Vivani Medical

Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent

May 23, 2025 By Sean Whooley

Elixir-Dynamx

Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system. The 445-patient BIOADAPTOR trial compares DynamX to the standard of care Medtronic Resolute Onyx drug-eluting stent (DES). It took place across 34 centers in Japan, Europe and New Zealand. Data — shared this week at EuroPCR 2025 in […]

Filed Under: Cardiovascular, Clinical Trials, Implants, Stents Tagged With: Elixir Medical Corporation

Senseonics closes public offering, private placement with Abbott

May 22, 2025 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced that it closed its previously announced public offering and private placement with Abbott. Last week, the long-term continuous glucose monitor maker said it commenced an underwritten public offering of common stock worth $50 million. At the same time, it entered into a securities purchase agreement with another CGM maker — Abbott. Under […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

Senseonics opens $50M public offering, $25M private placement with Abbott

May 15, 2025 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of stock offered in the public offering. All shares to be […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Patient Monitoring, Technology Tagged With: Senseonics

Glucotrack can proceed with long-term glucose monitor study in Australia

May 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Senseonics posts Q2 sales beat, submits 365-day CGM for CE mark

May 8, 2025 By Sean Whooley

Senseonics logo

Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street. Shares of SENS fell 5% to 70¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $14.3 million. That equals 2¢ per share on sales of $6.26 million for the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Patient Monitoring, Technology Tagged With: Senseonics

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 24
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS